Find Oncology Drugs in Phase I Clinical Development in UNITED KINGDOM

Lead Product(s): Navicixizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Oncologie

Deal Size: $306.0 million Upfront Cash: $4.0 million

Deal Type: Licensing Agreement January 13, 2020

Details:

Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.

Lead Product(s): MRx0518,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

The study is the second opened as part of a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.